JGC
AUPH icon

J. Goldman & Co’s Aurinia Pharmaceuticals AUPH Stock Holding History

J. Goldman & Co’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,500
Closed -$149K – 568
2025
Q3 		$149K Buy
+13,500
New +$147K ﹤0.01% 424
2024
Q1 		– Sell
-113,550
Closed -$1.02M – 412
2023
Q4 		$1.02M Sell
113,550
-273,003
-71% -$2.25M 0.04% 230
2023
Q3 		$3M Sell
386,553
-165,854
-30% -$1.62M 0.11% 170
2023
Q2 		$5.35M Buy
+552,407
New +$5.73M 0.19% 128
2020
Q4 		– Sell
-97,382
Closed -$1.43M – 368
2020
Q3 		$1.43M Sell
97,382
-79,816
-45% -$1.16M 0.1% 190
2020
Q2 		$2.88M Buy
177,198
+29,584
+20% +$474K 0.18% 135
2020
Q1 		$2.14M Sell
147,614
-4,904
-3% -$86.5K 0.26% 94
2019
Q4 		$3.09M Buy
+152,518
New +$1.4M 0.22% 112

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

J. Goldman & Co's AUPH Position: Q4 2025 in Review

J. Goldman & Co sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2025, closing a stake of 13,500 shares — an estimated $149K sold.

J. Goldman & Co first reported a position in AUPH in Q4 2019 and held it in 8 quarters. The position peaked at $5.35M in Q2 2023. 255 funds tracked by Wall St. Rank hold AUPH as of Q4 2025.

  • J. Goldman & Co reported no remaining Aurinia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • J. Goldman & Co sold 13,500 Aurinia Pharmaceuticals shares in Q4 2025, an estimated $149K.
  • J. Goldman & Co first reported a position in Aurinia Pharmaceuticals in Q4 2019 and held it in 8 quarters.
  • J. Goldman & Co's Aurinia Pharmaceuticals position peaked at $5.35M in Q2 2023.
  • 255 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.